Clinical trial • Phase III • Ophthalmology

SURABGENE LOMPARVOVEC (AAV8 vector encoding anti-VEGF antigen-binding fragment; synonyms: RGX-314, ABBV-RGX-314) for Neovascular age-related macular degeneration

Phase III trial of SURABGENE LOMPARVOVEC (AAV8 vector encoding anti-VEGF antigen-binding fragment; synonyms: RGX-314, ABBV-RGX-314) for Neovascular age-re…

Overview

Trial Therapeutic Area
Ophthalmology
Trial Disease
Neovascular age-related macular degeneration
Trial Stage
Phase III
Drug Modality
Gene therapy | Monoclonal antibody

Key dates

Initial CTIS Submission Date
17-07-2025
First CTIS Authorization Date
02-12-2025

Trial design

Randomised, ranibizumab (lucentis 10 mg/ml solution for injection in pre-filled syringe); administered intravitreally on a prn basis per protocol-specified criteria during year 1 and subsequently on a prn schedule that mimics real-world clinical practice after year 1.-controlled Phase III trial in Austria, Belgium, Bulgaria and others.

Randomised
Yes
Comparator
Ranibizumab (Lucentis 10 mg/ml solution for injection in pre-filled syringe); administered intravitreally on a PRN basis per protocol-specified criteria during Year 1 and subsequently on a PRN schedule that mimics real-world clinical practice after Year 1.
Real World Control
Yes
Target Sample Size
289
Trial Duration For Participant
1095

Eligibility

Recruits 289 No vulnerable populations selected. Trial enrols adult participants only (public title and inclusion criteria specify adult participants). Informed consent is obtained from participants; country-specific ICFs (including pregnant partner ICFs) are provided. No paediatric assent procedures are indicated..

Vulnerable Population
No vulnerable populations selected. Trial enrols adult participants only (public title and inclusion criteria specify adult participants). Informed consent is obtained from participants; country-specific ICFs (including pregnant partner ICFs) are provided. No paediatric assent procedures are indicated.

Inclusion criteria

  • {"criterion_text":"- Pseudophakic (at least 12 weeks post cataract surgery at Screening Visit 1 [Week –6]) in the study eye"}
  • {"criterion_text":"- Must have a diagnosis of CNV secondary to AMD in the study eye"}
  • {"criterion_text":"- Must have received at least 2 intravitreal anti-VEGF injections in the past 6 months in the study eye prior to Screening Visit 1 (Week –6) and have been responsive (determined by investigator)"}

Exclusion criteria

  • {"criterion_text":"- CNV or macular edema in the study eye that is secondary to any causes other than AMD."}
  • {"criterion_text":"- Study eye with nAMD diagnosed > 4 years from Screening Visit 1"}
  • {"criterion_text":"- Any subretinal hemorrhage in the study eye > 50% of the total lesion area or within the parafovea (3 mm center of the macula), as determined by the central reading center."}
  • {"criterion_text":"- History of retinal detachment, retinal tear or macular hole in the study eye that, in the opinion of the investigator, may preclude successful subretinal injection of surabgene lomparvovec."}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Annualized intravitreal anti-VEGF injection rate from Week 6 through Week 54.","definition_or_measurement_approach":"Annualized intravitreal anti-VEGF injection rate measured from Week 6 through Week 54 (rate of intravitreal anti-VEGF injections per year calculated over this interval)."}

Secondary endpoints

  • {"endpoint_text":"- Change from Baseline in BCVA at Year 3.","definition_or_measurement_approach":"Change from baseline in best-corrected visual acuity (BCVA) measured at Year 3 compared to baseline."}
  • {"endpoint_text":"- Annualized intravitreal anti-VEGF injection rate from Week 6 through Year 3.","definition_or_measurement_approach":"Annualized intravitreal anti-VEGF injection rate measured from Week 6 through Year 3 (rate of injections per year over this interval)."}
  • {"endpoint_text":"- Incidence and severity of ocular AEs in the study eye and contralateral eye","definition_or_measurement_approach":"Recording and grading of ocular adverse events (incidence and severity) in both study and contralateral eyes per study safety reporting procedures."}
  • {"endpoint_text":"- Change from Baseline in area of macular atrophy based on FAF at assessed time points in the study eye","definition_or_measurement_approach":"Change from baseline in macular atrophy area assessed by fundus autofluorescence (FAF) imaging at scheduled time points."}

Recruitment

Planned Sample Size
289
Recruitment Window Months
85
Consent Approach
Informed consent obtained from adult participants. Country-specific subject information and informed consent forms (ICFs) are provided (multiple languages / country-specific ICFs available as listed in the application documents). Pregnant-partner ICFs are available where applicable. Consent is provided by the participant; no paediatric assent is indicated.

Geography

Total Number Of Sites
75
Total Number Of Participants
272

Austria

Earliest CTIS Part Ii Submission Date
30-09-2025
Latest Decision Or Authorization Date
08-12-2025
Processing Time Days
69
Number Of Sites
5
Number Of Participants
20

Sites

Site Name
Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH
Department Name
Department of Opthalmology
Principal Investigator Name
Herbert Reitsamer
Principal Investigator Email
h.reitsamer@salk.at
Contact Person Name
Herbert Reitsamer
Contact Person Email
h.reitsamer@salk.at
Site Name
Medizinische Universitaet Innsbruck
Department Name
Department of Ophthalmology and Optometry
Principal Investigator Name
Matus Rehak
Principal Investigator Email
matus.rehak@i-med.ac.at
Contact Person Name
Matus Rehak
Contact Person Email
matus.rehak@i-med.ac.at
Site Name
NOE Landesgesundheitsagentur
Department Name
Department of Opthalmology
Principal Investigator Name
Sebastian Waldstein
Principal Investigator Email
sebastian.waldstein@mistelbach.lknoe.at
Contact Person Name
Sebastian Waldstein
Site Name
Medical University Of Graz
Department Name
Department of Ophthalmology
Principal Investigator Name
Anton Haas
Principal Investigator Email
anton.haas@medunigraz.at
Contact Person Name
Anton Haas
Contact Person Email
anton.haas@medunigraz.at
Site Name
Johannes Kepler University Linz
Department Name
Department of Ophthalmology and Optometry
Principal Investigator Name
Matthias Bolz
Principal Investigator Email
matthias.bolz@kepleruniklinikum.at
Contact Person Name
Matthias Bolz

Belgium

Earliest CTIS Part Ii Submission Date
06-10-2025
Latest Decision Or Authorization Date
03-12-2025
Processing Time Days
58
Number Of Sites
2
Number Of Participants
8

Sites

Site Name
UZ Leuven
Department Name
Oogheelkunde
Principal Investigator Name
Julie Jacob
Principal Investigator Email
julie.jacob@uzleuven.be
Contact Person Name
Julie Jacob
Contact Person Email
julie.jacob@uzleuven.be
Site Name
Universitair Ziekenhuis Gent
Department Name
Oogheelkunde
Principal Investigator Name
Julie De Zaeytijd
Principal Investigator Email
julie.dezaeytijd@uzgent.be
Contact Person Name
Julie De Zaeytijd
Contact Person Email
julie.dezaeytijd@uzgent.be

Bulgaria

Earliest CTIS Part Ii Submission Date
13-10-2025
Latest Decision Or Authorization Date
08-12-2025
Processing Time Days
56
Number Of Sites
4
Number Of Participants
16

Sites

Site Name
Assoc. Prof. Dr. Desislava Koleva Outpatient clinic for individual practice for specialized medical assistance in eye diseases "St. Luka" EOOD
Principal Investigator Name
Desislava Koleva-Georgieva
Principal Investigator Email
dr_desikoleva@yahoo.com
Contact Person Name
Desislava Koleva-Georgieva
Contact Person Email
dr_desikoleva@yahoo.com
Site Name
Specialized Eye Hospital For Active Treatment Burgas OOD
Department Name
Department - Eye Diseases
Principal Investigator Name
Dimitar Grupchev
Principal Investigator Email
dgrupchev@gmail.com
Contact Person Name
Dimitar Grupchev
Contact Person Email
dgrupchev@gmail.com
Site Name
Medical Center Vereya EOOD
Principal Investigator Name
Dimitar Dzhelebov
Principal Investigator Email
dzhelebov@gmail.com
Contact Person Name
Dimitar Dzhelebov
Contact Person Email
dzhelebov@gmail.com
Site Name
Specialized Hospital For Active Treatment Of Eye Diseases Zora OOD
Department Name
Department - Eye Diseases
Principal Investigator Name
Iva Petkova
Principal Investigator Email
ivapetkova@abv.bg
Contact Person Name
Iva Petkova
Contact Person Email
ivapetkova@abv.bg

Croatia

Earliest CTIS Part Ii Submission Date
17-09-2025
Latest Decision Or Authorization Date
08-12-2025
Processing Time Days
82
Number Of Sites
3
Number Of Participants
12

Sites

Site Name
University Hospital Sveti Duh
Department Name
Ophthalmology
Principal Investigator Name
Damir Bosnar
Principal Investigator Email
ocna@kbsd.hr
Contact Person Name
Damir Bosnar
Contact Person Email
ocna@kbsd.hr
Site Name
Specijalna bolnica Svjetlost
Department Name
Ophthalmology
Principal Investigator Name
Ratimir Lazić
Principal Investigator Email
tajnica@svjetlost.hr
Contact Person Name
Ratimir Lazić
Contact Person Email
tajnica@svjetlost.hr
Site Name
University Hospital Centre Zagreb
Department Name
Ophthalmology
Principal Investigator Name
Tomislav Jukić
Principal Investigator Email
predstojnik.oci@kbc-zagreb.hr
Contact Person Name
Tomislav Jukić
Contact Person Email
predstojnik.oci@kbc-zagreb.hr

Czechia

Earliest CTIS Part Ii Submission Date
10-10-2025
Latest Decision Or Authorization Date
04-12-2025
Processing Time Days
55
Number Of Sites
5
Number Of Participants
20

Sites

Site Name
Fakultni Nemocnice Kralovske Vinohrady
Department Name
Oftalmologická klinika
Principal Investigator Name
Miroslav Veith
Principal Investigator Email
miroslav.veith@fnkv.cz
Contact Person Name
Miroslav Veith
Contact Person Email
miroslav.veith@fnkv.cz
Site Name
Fakultni Nemocnice Ostrava
Department Name
Ocni klinika FNO
Principal Investigator Name
Jan Nemcansky
Principal Investigator Email
jan.nemcansky@fno.cz
Contact Person Name
Jan Nemcansky
Contact Person Email
jan.nemcansky@fno.cz
Site Name
Vseobecna Fakultni Nemocnice V Praze
Department Name
Ocni klinika VFN
Principal Investigator Name
Bohdan Kousal
Principal Investigator Email
bohdan.kousal@vfn.cz
Contact Person Name
Bohdan Kousal
Contact Person Email
bohdan.kousal@vfn.cz
Site Name
Axon Clinical s.r.o.
Department Name
Ocni oddeleni
Principal Investigator Name
Jan Ernest
Principal Investigator Email
jan.ernest@axon-clinical.com
Contact Person Name
Jan Ernest
Contact Person Email
jan.ernest@axon-clinical.com
Site Name
Ustredni Vojenska Nemocnice Vojenska Fakultni Nemocnice Praha
Department Name
Ocni klinika UVN
Principal Investigator Name
Martin Šín
Principal Investigator Email
sin.martin@uvn.cz
Contact Person Name
Martin Šín
Contact Person Email
sin.martin@uvn.cz

France

Earliest CTIS Part Ii Submission Date
22-10-2025
Latest Decision Or Authorization Date
11-05-2026
Processing Time Days
201
Number Of Sites
13
Number Of Participants
40

Sites

Site Name
Pole Vision Val D'Ouest
Department Name
Ophthalmology
Principal Investigator Name
Pierre Loic CORNUT
Principal Investigator Email
direction@polevision.fr
Contact Person Name
Pierre Loic CORNUT
Contact Person Email
direction@polevision.fr
Site Name
Centre Hospitalier Universitaire De Nantes
Department Name
Ophthalmology
Principal Investigator Name
Olivier LEBRETON
Principal Investigator Email
olivier.lebreton@chu-nantes.fr
Contact Person Name
Olivier LEBRETON
Contact Person Email
olivier.lebreton@chu-nantes.fr
Site Name
Centre Hospitalier Universitaire De Bordeaux
Department Name
Ophthalmology
Principal Investigator Name
Marie-Noelle DELYFER
Principal Investigator Email
marie-noelle.delyfer@chu-bordeaux.fr
Contact Person Name
Marie-Noelle DELYFER
Site Name
Clinique Juge
Department Name
Ophtalmology
Principal Investigator Name
François Devin
Principal Investigator Email
fdbm.retine@gmail.com
Contact Person Name
François Devin
Contact Person Email
fdbm.retine@gmail.com
Site Name
Centre Hospitalier Universitaire De Nice
Department Name
Ophthalmology
Principal Investigator Name
Stéphanie Baillif
Principal Investigator Email
baillif.s@chu-nice.fr
Contact Person Name
Stéphanie Baillif
Contact Person Email
baillif.s@chu-nice.fr
Site Name
Institut Ophtalmologique De l'Ouest Jules Verne
Department Name
Clinique Jules Verne
Principal Investigator Name
Frank BECQUET
Principal Investigator Email
frankbecquet@yahoo.fr
Contact Person Name
Frank BECQUET
Contact Person Email
frankbecquet@yahoo.fr
Site Name
Hospital Edouard Herriot
Department Name
Ophthalmology
Principal Investigator Name
Corinne DOT
Principal Investigator Email
corinne.dot@chu-lyon.fr
Contact Person Name
Corinne DOT
Contact Person Email
corinne.dot@chu-lyon.fr
Site Name
Centre Monticelli Paradis D Ophtalmologie
Department Name
Ophtalmology
Principal Investigator Name
François DEVIN
Principal Investigator Email
fdbm.retine@gmail.com
Contact Person Name
François DEVIN
Contact Person Email
fdbm.retine@gmail.com
Site Name
Selarl Retine Tourny
Department Name
Centre Rétine Galien
Principal Investigator Name
Laurence Rosier
Principal Investigator Email
Laurence.rosier@retinegallien.com
Contact Person Name
Laurence Rosier
Site Name
Centre Hospitalier Intercommunal Creteil
Department Name
Ophthalmology
Principal Investigator Name
Eric SOUEID
Principal Investigator Email
eric.soueid@chicreteil.fr
Contact Person Name
Eric SOUEID
Contact Person Email
eric.soueid@chicreteil.fr
Site Name
Centre Hospitalier National d'Ophtalmologie des Quize-Vingts
Department Name
Ophthalmology
Principal Investigator Name
Jean-François GIRMENS
Principal Investigator Email
nbrouk@15-20.fr
Contact Person Name
Jean-François GIRMENS
Contact Person Email
nbrouk@15-20.fr
Site Name
Fondation A De Rothschild
Department Name
Ophthalmology
Principal Investigator Name
Sébastien Bruneau
Principal Investigator Email
sbruneau@for.paris
Contact Person Name
Sébastien Bruneau
Contact Person Email
sbruneau@for.paris

Germany

Earliest CTIS Part Ii Submission Date
24-10-2025
Latest Decision Or Authorization Date
22-04-2026
Processing Time Days
180
Number Of Sites
12
Number Of Participants
40

Sites

Site Name
Universitaetsklinikum Ulm AöR
Department Name
Klinik fuer Augenheilkunde
Principal Investigator Name
Armin Wolf
Contact Person Name
Armin Wolf
Site Name
LMU Klinikum Muenchen AöR
Department Name
Augenklinik und Poliklinik
Principal Investigator Name
Siegfried Priglinger
Principal Investigator Email
Maximilian.gerhardt@med.uni-muenchen.de
Contact Person Name
Siegfried Priglinger
Site Name
Medizinische Hochschule Hannover
Department Name
Universitaetsklinik fuer Augenheilkunde
Principal Investigator Name
Ekaterina Sokolenko
Principal Investigator Email
Augenklinik.Studien@mh-hannover.de
Contact Person Name
Ekaterina Sokolenko
Site Name
Universitaetsklinikum Bonn AöR
Department Name
Klinik fuer Augenheilkunde
Principal Investigator Name
Frank G Holz
Principal Investigator Email
Gamze.Bildik@ukbonn.de
Contact Person Name
Frank G Holz
Contact Person Email
Gamze.Bildik@ukbonn.de
Site Name
Universitaet Muenster
Department Name
Klinik fuer Augenheilkunde
Principal Investigator Name
Nicole Eter
Principal Investigator Email
Augenklinik-studien@ukmuenster.de
Contact Person Name
Nicole Eter
Site Name
Charite Universitaetsmedizin Berlin KöR
Department Name
Klinik fuer Augenheilkunde
Principal Investigator Name
Antonia Joussen
Principal Investigator Email
studien-augenklinik-cbf@charite.de
Contact Person Name
Antonia Joussen
Site Name
Klinikum der Stadt Ludwigshafen am Rhein gGmbH
Department Name
Augenklinik
Principal Investigator Name
Lars-Olof Hattenbach
Principal Investigator Email
Studien_augenklinik@klilu.de
Contact Person Name
Lars-Olof Hattenbach
Contact Person Email
Studien_augenklinik@klilu.de
Site Name
Medical Center - University Of Freiburg
Department Name
Klinik fuer Augenheilkunde
Principal Investigator Name
Hansjürgen Agostini
Principal Investigator Email
hansjuergen.agostini@uniklinik-freiburg.de
Contact Person Name
Hansjürgen Agostini
Site Name
Universitaetsklinikum Tuebingen AöR
Department Name
Universitaets-Augenklinik
Principal Investigator Name
Karl Ulrich Bartz-Schmidt
Principal Investigator Email
studien.augenklinik@med.uni-tuebingen.de
Contact Person Name
Karl Ulrich Bartz-Schmidt
Site Name
Universitaetsmedizin Goettingen
Department Name
Klinik fuer Augenheilkunde
Principal Investigator Name
Sebastian Bemme
Contact Person Name
Sebastian Bemme
Site Name
University Medical Center Hamburg-Eppendorf
Department Name
Augenheilkunde
Principal Investigator Name
Martin Spitzer
Principal Investigator Email
Studien-Augenklinik@uke.de
Contact Person Name
Martin Spitzer
Contact Person Email
Studien-Augenklinik@uke.de
Site Name
Universitaetsklinikum Schleswig-Holstein AöR
Department Name
Klinik fuer Augenheilkunde
Principal Investigator Name
Salvatore Grisanti
Principal Investigator Email
Studien.augenklinik.luebeck@uksh.de
Contact Person Name
Salvatore Grisanti

Greece

Earliest CTIS Part Ii Submission Date
31-10-2025
Latest Decision Or Authorization Date
02-12-2025
Processing Time Days
32
Number Of Sites
4
Number Of Participants
16

Sites

Site Name
General Hospital Of Athens G Gennimatas
Department Name
First University Ophthalmology Department
Principal Investigator Name
Ilias Georgalas
Principal Investigator Email
igeorgalas@yahoo.com
Contact Person Name
Ilias Georgalas
Contact Person Email
igeorgalas@yahoo.com
Site Name
University General Hospital Of Heraklion
Department Name
Ophthalmology Department
Principal Investigator Name
Miltiadis Tsilimbaris
Principal Investigator Email
tsilimb@med.uoc.gr
Contact Person Name
Miltiadis Tsilimbaris
Contact Person Email
tsilimb@med.uoc.gr
Site Name
University General Hospital Attikon General Hospital Of West Attica H Agia Varvara
Department Name
2nd University Department of Ophthalmology
Principal Investigator Name
Eirini Chatziralli
Principal Investigator Email
eirchat@med.uoa.gr
Contact Person Name
Eirini Chatziralli
Contact Person Email
eirchat@med.uoa.gr
Site Name
General University Hospital Of Larissa
Department Name
University Eye Clinic
Principal Investigator Name
Sofia Androudi
Principal Investigator Email
androudi@otenet.gr
Contact Person Name
Sofia Androudi
Contact Person Email
androudi@otenet.gr

Hungary

Earliest CTIS Part Ii Submission Date
08-10-2025
Latest Decision Or Authorization Date
08-12-2025
Processing Time Days
61
Number Of Sites
4
Number Of Participants
16

Sites

Site Name
Budapest Retina Associates Kft.
Department Name
Budapest Retina Associates
Principal Investigator Name
Andras Seres
Principal Investigator Email
seres@budapestretina.hu
Contact Person Name
Andras Seres
Contact Person Email
seres@budapestretina.hu
Site Name
Semmelweis University
Department Name
Szemeszeti Klinika, Szemeszeti Klinikai Kutato Kozpont
Principal Investigator Name
Andras Papp
Principal Investigator Email
papp.andras1@semmelweis.hu
Contact Person Name
Andras Papp
Contact Person Email
papp.andras1@semmelweis.hu
Site Name
University Of Debrecen
Department Name
Szemklinika
Principal Investigator Name
Attila Vajas
Principal Investigator Email
vajasa@gmail.com
Contact Person Name
Attila Vajas
Contact Person Email
vajasa@gmail.com
Site Name
Nozologen Kft.
Department Name
Ganglion Orvosi Kozpont
Principal Investigator Name
Balazs Varsanyi
Principal Investigator Email
info@ganglion.hu
Contact Person Name
Balazs Varsanyi
Contact Person Email
info@ganglion.hu

Portugal

Earliest CTIS Part Ii Submission Date
19-09-2025
Latest Decision Or Authorization Date
02-12-2025
Processing Time Days
74
Number Of Sites
3
Number Of Participants
12

Sites

Site Name
Unidade Local De Saude De Sao Jose E.P.E.
Department Name
Opthalmic Service
Principal Investigator Name
Rita Flores
Principal Investigator Email
ritamariaflores@gmail.com
Contact Person Name
Rita Flores
Contact Person Email
ritamariaflores@gmail.com
Site Name
Unidade Local De Saude De Coimbra E.P.E.
Department Name
Opthalmic Service
Principal Investigator Name
João Marques
Principal Investigator Email
marquesjoaopedro@gmail.com
Contact Person Name
João Marques
Contact Person Email
marquesjoaopedro@gmail.com
Site Name
Unidade Local De Saude De Santo Antonio E.P.E.
Department Name
Opthalmic Service
Principal Investigator Name
Miguel Lume
Principal Investigator Email
miguelribeirolume@gmail.com
Contact Person Name
Miguel Lume
Contact Person Email
miguelribeirolume@gmail.com

Slovakia

Earliest CTIS Part Ii Submission Date
02-10-2025
Latest Decision Or Authorization Date
02-12-2025
Processing Time Days
61
Number Of Sites
3
Number Of Participants
12

Sites

Site Name
University Hospital Bratislava
Department Name
Ophtalmology
Principal Investigator Name
Petr Kolar
Principal Investigator Email
ocne.sekretariat@pe.unb.sk
Contact Person Name
Petr Kolar
Contact Person Email
ocne.sekretariat@pe.unb.sk
Site Name
Fakultna Nemocnica Trencín
Department Name
Ophtalmology
Principal Investigator Name
Marek Kacerik
Principal Investigator Email
marek.kacerik@fntn.sk
Contact Person Name
Marek Kacerik
Contact Person Email
marek.kacerik@fntn.sk
Site Name
Fakultna Nemocnica S Poliklinikou Zilina
Department Name
Ophtalmology
Principal Investigator Name
Milan Veselovsky
Principal Investigator Email
lubica.libicova@fnspza.sk
Contact Person Name
Milan Veselovsky
Contact Person Email
lubica.libicova@fnspza.sk

Spain

Earliest CTIS Part Ii Submission Date
08-10-2025
Latest Decision Or Authorization Date
23-02-2026
Processing Time Days
138
Number Of Sites
11
Number Of Participants
40

Sites

Site Name
Metavision Arruzafa S.L.
Department Name
Ophthalmology
Principal Investigator Name
Juan Manuel Cubero Parra
Principal Investigator Email
jmcp@hospitalarruzafa.com
Contact Person Name
Juan Manuel Cubero Parra
Contact Person Email
jmcp@hospitalarruzafa.com
Site Name
Hospital Universitario Virgen De La Macarena
Department Name
Ophthalmology
Principal Investigator Name
Enrique Rodríguez de la Rua Franch
Principal Investigator Email
erdelarua@gmail.com
Contact Person Name
Enrique Rodríguez de la Rua Franch
Contact Person Email
erdelarua@gmail.com
Site Name
Instituto Clinic De Oftalmologia
Department Name
Ophthalmology
Principal Investigator Name
Anna Sala Puigdollers
Principal Investigator Email
ansala@clinic.cat
Contact Person Name
Anna Sala Puigdollers
Contact Person Email
ansala@clinic.cat
Site Name
Hospital Universitari Vall D Hebron
Department Name
Ophthalmology
Principal Investigator Name
Miguel Ángel Zapata Victori
Principal Investigator Email
miguelangel.zapata@vallhebron.cat
Contact Person Name
Miguel Ángel Zapata Victori
Site Name
Hospital Universitario Y Politecnico La Fe
Department Name
Ophthalmology
Principal Investigator Name
Patricia Udaondo Mirete
Principal Investigator Email
draudaondo@gmail.com
Contact Person Name
Patricia Udaondo Mirete
Contact Person Email
draudaondo@gmail.com
Site Name
Hospital Universitario Donostia
Department Name
Ophthalmology
Principal Investigator Name
Cristina Irigoyen Laborra
Principal Investigator Email
cristina.irigoyenlaborra@osakidetza.eus
Contact Person Name
Cristina Irigoyen Laborra
Site Name
Hospital Clinico Universitario Lozano Blesa
Department Name
Ophthalmology
Principal Investigator Name
Francisco Javier Ascaso Puyuelo
Principal Investigator Email
jascaso@gmail.com
Contact Person Name
Francisco Javier Ascaso Puyuelo
Contact Person Email
jascaso@gmail.com
Site Name
Centro De Oftalmologia Barraquer S.A.
Department Name
Ophthalmology
Principal Investigator Name
Santiago Abengoechea Hernández
Principal Investigator Email
sah@barraquer.com
Contact Person Name
Santiago Abengoechea Hernández
Contact Person Email
sah@barraquer.com
Site Name
Hospital Universitario Puerta De Hierro De Majadahonda
Department Name
Ophthalmology
Principal Investigator Name
Jose María Ruiz Moreno
Principal Investigator Email
josemaria.ruiz@uclm.es
Contact Person Name
Jose María Ruiz Moreno
Contact Person Email
josemaria.ruiz@uclm.es
Site Name
Instituto Oftalmologico Fernandez-Vega S.L.
Department Name
Ophthalmology
Principal Investigator Name
Álvaro Fernández-Vega Sanz
Principal Investigator Email
investigacion@fernandez-vega.com
Contact Person Name
Álvaro Fernández-Vega Sanz
Site Name
Hospital Universitario 12 De Octubre
Department Name
Ophthalmology
Principal Investigator Name
Luis Francisco Moreno García
Principal Investigator Email
Luisfco.moreno@salud.madrid.org
Contact Person Name
Luis Francisco Moreno García

Italy

Earliest CTIS Part Ii Submission Date
07-10-2025
Latest Decision Or Authorization Date
24-03-2026
Processing Time Days
168
Number Of Sites
6
Number Of Participants
20

Sites

Site Name
Azienda USL IRCCS Di Reggio Emilia
Department Name
Ocular Immunology Unit
Principal Investigator Name
Luca Cimino
Principal Investigator Email
luca.cimino@ausl.re.it
Contact Person Name
Luca Cimino
Contact Person Email
luca.cimino@ausl.re.it
Site Name
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Department Name
UOC Oculistica
Principal Investigator Name
Angelo Maria Minnella
Principal Investigator Email
angelomaria.minnella@policlinicogemelli.it
Contact Person Name
Angelo Maria Minnella
Site Name
Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino
Department Name
Oculistica
Principal Investigator Name
Michele Reibaldi
Principal Investigator Email
michele.reibaldi@unito.it
Contact Person Name
Michele Reibaldi
Contact Person Email
michele.reibaldi@unito.it
Site Name
Azienda Ospedaliero Universitaria Careggi
Department Name
SOD Ottica Fisiopatologica
Principal Investigator Name
Fabrizio Giansanti
Principal Investigator Email
fabrizio.giansanti@unifi.it
Contact Person Name
Fabrizio Giansanti
Contact Person Email
fabrizio.giansanti@unifi.it
Site Name
University Hospital Of Ferrara
Department Name
Dipartimento di Medicina Traslazionale e per la Romagna
Principal Investigator Name
Marco Mura
Principal Investigator Email
dmtr@unife.it
Contact Person Name
Marco Mura
Contact Person Email
dmtr@unife.it
Site Name
Azienda Ospedaliero Universitaria Delle Marche
Department Name
Clinica Oculistica
Principal Investigator Name
Cesare Mariotti
Principal Investigator Email
cesare.mariotti@ospedaliriuniti.marche.it
Contact Person Name
Cesare Mariotti

Sponsor

Primary sponsor

Full Name
AbbVie Deutschland GmbH & Co. KG
Organisation Type
Pharmaceutical company
Country Of Registered Address
Germany

Contract research organisations

Name
Merit CRO Inc.
Responsibilities
Central reading center
Name
Iqvia Rds Inc.
Responsibilities
IRT-global.helpdesk (operational support) (code: 3)
Name
WCG Clinical Inc.
Responsibilities
Patient Recruitment
Name
Veranex Inc.
Responsibilities
Investigator training

Third parties

  • {"country":"United States","full_name":"Veeva Systems Inc.","duties_or_roles":"codes: 6,7","organisation_type":"Non-Pharmaceutical company"}
  • {"country":"United States","full_name":"Merit CRO Inc.","duties_or_roles":"Central reading center","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Azenta US Inc.","duties_or_roles":"code: 4","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Optymedge LLC","duties_or_roles":"Visual function exam certification","organisation_type":"Laboratory/Research/Testing facility"}
  • {"country":"United States","full_name":"Avantor Inc.","duties_or_roles":"Study equipment rental","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Greenphire LLC","duties_or_roles":"Patient transportation","organisation_type":"Non-Pharmaceutical company"}
  • {"country":"Switzerland","full_name":"Labcorp Central Laboratory Services SARL","duties_or_roles":"code: 4","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"WCG Clinical Inc.","duties_or_roles":"Patient Recruitment","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Iqvia Rds Inc.","duties_or_roles":"code: 3","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Veranex Inc.","duties_or_roles":"Investigator training","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Cytel Inc.","duties_or_roles":"Data monitoring committee","organisation_type":"Non-Pharmaceutical company"}

Investigational products

Investigational Product Name
Surabgene Lomparvovec (ABBV-RGX-314)
Active Substance
SURABGENE LOMPARVOVEC (AAV8 vector encoding anti-VEGF antigen-binding fragment; synonyms: RGX-314, ABBV-RGX-314)
Modality
Gene therapy
Routes Of Administration
SUBRETINAL USE
Route
Subretinal
Authorisation Status
Not authorised
Investigational Product Name
Lucentis 10 mg/ml solution for injection in pre-filled syringe (ranibizumab)
Active Substance
RANIBIZUMAB
Modality
Monoclonal antibody
Routes Of Administration
INTRAVITREAL USE
Route
Intravitreal
Authorisation Status
Authorised
Frequency
PRN per protocol (Year 1) then PRN real-world schedule after Year 1

Related trials

Other published trials that may interest you.